Wilmington Savings Fund Society FSB Lowers Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Wilmington Savings Fund Society FSB cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 15.8% during the fourth quarter, Holdings Channel reports. The firm owned 4,786 shares of the medical device company’s stock after selling 899 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in DexCom were worth $372,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Livforsakringsbolaget Skandia Omsesidigt lifted its holdings in DexCom by 290.7% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 3,387 shares of the medical device company’s stock worth $227,000 after buying an additional 2,520 shares in the last quarter. Exchange Traded Concepts LLC increased its position in shares of DexCom by 39.5% during the third quarter. Exchange Traded Concepts LLC now owns 12,276 shares of the medical device company’s stock worth $823,000 after acquiring an additional 3,474 shares during the period. Sapient Capital LLC acquired a new stake in shares of DexCom in the third quarter valued at $366,000. Creative Planning boosted its holdings in DexCom by 22.3% in the third quarter. Creative Planning now owns 59,573 shares of the medical device company’s stock valued at $3,994,000 after purchasing an additional 10,880 shares during the period. Finally, Swedbank AB grew its stake in DexCom by 15.2% during the 3rd quarter. Swedbank AB now owns 213,864 shares of the medical device company’s stock worth $14,337,000 after purchasing an additional 28,289 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Down 2.1 %

DXCM opened at $86.38 on Wednesday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The business’s 50 day moving average is $81.94 and its two-hundred day moving average is $74.97. The firm has a market cap of $33.74 billion, a price-to-earnings ratio of 51.72, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Leerink Partners reduced their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Royal Bank of Canada reduced their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Oppenheimer lowered their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $98.41.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 42,342 shares of company stock worth $3,628,069. Insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.